Partisil® and Partisphere® HPLC column ranges acquired by Hichrom from Whatman/GE Healthcare
Hichrom Limited are pleased to announce the acquisition of the Partisil® and Partisphere® HPLC column consumable product line from Whatman, a division of GE Healthcare. Based in the UK, Hichrom are a leading European manufacturer and distributor of HPLC columns, consumables and media, with manufacturing facilities accredited to both ISO9001 (Quality) and ISO14001 (Environmental) standards.
Hichrom Limited are pleased to announce the acquisition of the Partisil® and Partisphere® HPLC column consumable product line from Whatman, a division of GE Healthcare. Based in the UK, Hichrom are a leading European manufacturer and distributor of HPLC columns, consumables and media, with manufacturing facilities accredited to both ISO9001 (Quality) and ISO14001 (Environmental) standards.
Hichrom have worked closely with GE Healthcare during the manufacture of these products for a number of years, and as such manufacturing protocols, product specifications and part numbers will remain unaffected by the acquisition.
Additionally, Hichrom are pleased to confirm that Partisil and Partisphere column pricing will remain unchanged from the current GE Healthcare US List Price.
Until 16th April 2012, please continue to order these products as usual from GE Healthcare or their appointed distributors.
From 17th April 2012, Partisil and Partisphere products will no longer be available from GE Healthcare, and customers are requested to contact Hichrom directly to confirm their local distributor.
For further information on the acquisition of the Partisil and Partisphere HPLC column consumable product line please visit www.partisil.com
For details of Hichrom’s full range of HPLC products please visit ref="http://www.hichrom.co.uk">www.hichrom.co.uk
Mitigating High Sample Volume Consumption in AAV Aggregate Analysis Using a Biozen™ dSEC-7 by SEC-FL
April 15th 2024This application note showcases a Biozen dSEC-7 SEC chemistry/fluorescence detector solution, offering reliable AAV aggregate analysis in under 10 minutes with as little as 0.5 µL of sample. Across four AAV serotypes, resolution between monomer and aggregates remains consistently high, emphasizing Biozen dSEC-7's efficiency and ability to maintain accurate detection at minimal injection volumes. Ideal for routine testing, this solution ensures precise measurement of a CQA with streamlined sample consumption.
Adeno-Associated Virus (AAV) Serotype Screen Using a Biozen™ dSEC-7 Size Exclusion Column
April 15th 2024With its 700 Å large pore silica particle and hydrophilic diol-type surface chemistry, Biozen dSEC-7 provides excellent resolution of monomer from dimer peaks in under 8 minutes across four different AAV serotypes. This capability is crucial for optimizing gene therapy biopharmaceuticals, ensuring thorough analytical scrutiny to select the most appropriate serotype(s) for enhanced therapeutic outcomes and immunogenic profiles.
